| Identification | More | [Name]
Clopidogrel hydrogen sulfate | [CAS]
135046-48-9 | [Synonyms]
(2-chlorophenyl)-6,7╟dihydrothieno[3,2-c]pyridine-5-(4h)-acetic acid methyl ester sulfate
CLOPIDOGREL BISULFATE
CLOPIDOGREL BISULPHATE
CLOPIDOGREL HYDROGEN SULFATE
CLOPIDOGREL HYDROGEN SULPHATE
CLOPIDOGREL SULFATE
CLOPIDOGREL SULPHATE
PLAVIX
SR-25990C
SR-25990C, Plavix, Methyl (+)-(S)-a-(2-Chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)acetate, Hydrogen sulfate salt
Clopidogrel hydrogen sulfate
Methyl (S)-alpha-(2-Chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate hydrogen sulfate
SR-25990, Methyl (2-chlorophenyl)(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate hydrogen sulfate
Methyl 2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate hydrogen sulfate | [EINECS(EC#)]
603-890-4 | [Molecular Formula]
C15H16ClNO6S2 | [MDL Number]
MFCD00876395 | [Molecular Weight]
405.87 | [MOL File]
135046-48-9.mol |
| Chemical Properties | Back Directory | [Appearance]
Colorless to light yellow liqui | [Melting point ]
184°C | [alpha ]
D20 +55.10° (c = 1.891 in methanol) | [storage temp. ]
2-8°C | [solubility ]
DMSO: ~26mg/mL | [form ]
White powder | [color ]
white | [Usage]
Used as an antithrombotic | [InChIKey]
FDEODCTUSIWGLK-RSAXXLAASA-N | [CAS DataBase Reference]
135046-48-9(CAS DataBase Reference) |
| Safety Data | Back Directory | [Safety Statements ]
S22:Do not breathe dust .
S24/25:Avoid contact with skin and eyes . | [WGK Germany ]
3 | [HazardClass ]
IRRITANT |
| Hazard Information | Back Directory | [Chemical Properties]
Colorless to light yellow liqui | [Uses]
platelet aggregation inhibitors | [Uses]
rac-Clopidogrel Hydrogen Sulfate is used in the synthesis of Clopidogrel derivatives as platelet aggregation inhibitors. | [Uses]
Used as an antithrombotic | [Biochem/physiol Actions]
Inhibits ADP-induced platelet aggregation; anti-thrombotic drug. |
| Questions And Answer | Back Directory | [Anti-platelet aggregation drug]
Thrombosis caused by arterial atheromatous plaque leads to acute thrombosis cardiovascular and cerebrovascular events. In this pathogenesis, platelets play a central role, which has been fully studied.
Clopidogrel hydrogen sulfate is similar to ticlopidine, which is a new anti-platelet aggregation drug, successfully developed by French Sanofi-Synthelabo Fort for the prevention and treatment of heart, brain and other arterial circulation disorders caused by the high blood platelet aggregation, such as recent onset of stroke, myocardial infarction and patients diagnosed with peripheral arterial disease. Many countries have already used it, including United States, Europe and China. This product inhibited platelet activation by inhibiting adenosine diphosphate (ADP) pathway to inhibit platelet aggregation. Since clopidogrel hydrogen sulfate takes several days to achieve effective blood concentration, it does not apply to emergency treatment. Stop using 7 to 10 days, platelet function returned to normal state.
The above information is edited by the chemicalbook of Kui Ming.
|
|
|